[go: up one dir, main page]

BR9912327B1 - Inibidores da uroquinase - Google Patents

Inibidores da uroquinase

Info

Publication number
BR9912327B1
BR9912327B1 BRPI9912327-4B1A BR9912327A BR9912327B1 BR 9912327 B1 BR9912327 B1 BR 9912327B1 BR 9912327 A BR9912327 A BR 9912327A BR 9912327 B1 BR9912327 B1 BR 9912327B1
Authority
BR
Brazil
Prior art keywords
optionally
alkyl
substituted
aryl
ring
Prior art date
Application number
BRPI9912327-4B1A
Other languages
English (en)
Other versions
BR9912327A (pt
Inventor
Olaf Wilhelm
Viktor Magdolen
Joerg Stuerzebecher
John Foekens
Verena Lutz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8232314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9912327(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BR9912327A publication Critical patent/BR9912327A/pt
Publication of BR9912327B1 publication Critical patent/BR9912327B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0404Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205Radicals derived from carbonic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
BRPI9912327-4B1A 1998-07-20 1999-07-20 Inibidores da uroquinase BR9912327B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98113519 1998-07-20
PCT/EP1999/005145 WO2000004954A2 (de) 1998-07-20 1999-07-20 Neue urokinase-inhibitoren

Publications (2)

Publication Number Publication Date
BR9912327A BR9912327A (pt) 2001-05-02
BR9912327B1 true BR9912327B1 (pt) 2013-11-12

Family

ID=8232314

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9912327-4B1A BR9912327B1 (pt) 1998-07-20 1999-07-20 Inibidores da uroquinase

Country Status (12)

Country Link
US (2) US6624169B1 (pt)
EP (2) EP1264828B1 (pt)
JP (1) JP4603162B2 (pt)
AT (2) ATE230599T1 (pt)
AU (1) AU754958B2 (pt)
BR (1) BR9912327B1 (pt)
CA (1) CA2338073C (pt)
DE (2) DE59909210D1 (pt)
ES (2) ES2219607T3 (pt)
MX (1) MXPA01000553A (pt)
PT (1) PT1264828E (pt)
WO (1) WO2000004954A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1114024B1 (de) * 1998-09-18 2002-11-27 Pentapharm A.G. Urokinase-inhibitoren
DE10013715A1 (de) * 2000-03-20 2001-09-27 Wilex Biotechnology Gmbh Hochselektive Inhibitoren des Urokinase-Plasminogenaktivators
DE10029014A1 (de) * 2000-06-15 2001-12-20 Univ Schiller Jena Urokinase-Hemmstoffe
ATE386029T1 (de) 2001-03-21 2008-03-15 Wilex Ag Urokinase-inhibitoren
DE50310038D1 (de) * 2002-03-11 2008-08-07 Curacyte Ag Hemmstoffe der urokinase, ihre herstellung und verwendung
DE10225876A1 (de) 2002-06-11 2003-12-24 Wilex Ag Guanidinophenylalaninverbindungen als Urokinase-Inhibitoren
DE10233632A1 (de) * 2002-07-24 2004-02-05 Wilex Ag Formulierungen von Phenylalanin-Derivaten
DE10238048A1 (de) * 2002-07-25 2004-02-05 Wilex Ag Verfahren zur Herstellung von Phenylalanin-Derivaten
EP1525195A2 (de) * 2002-07-25 2005-04-27 Wilex AG Verfahren zur herstellung von phenylalanin-derivaten
DE10301300B4 (de) * 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
DE10322191B4 (de) * 2003-05-16 2014-02-27 The Medicines Company (Leipzig) Gmbh N-sulfonylierte Aminosäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
DE10323898A1 (de) 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
DE10342108A1 (de) * 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
EP1637529A1 (en) * 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
DE102004045720A1 (de) * 2004-09-21 2006-03-23 Wilex Ag Stabile Dosierungsform von Phenylalanin-Derivaten
ATE442842T1 (de) 2005-06-24 2009-10-15 Wilex Ag Verwendung von urokinase-inhibitoren zur behandlung und/oder vorbeugung von amyotrophischer lateralsklerose (als)
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
CA2800684A1 (en) * 2010-05-26 2011-12-01 Expression Pathology, Inc. Urokinase-type plasminogen activator protein/plasminogen activator inhibitor type-1 protein selected reaction monitoring assay
EP2590945B1 (en) 2010-07-07 2014-04-30 The Medicines Company (Leipzig) GmbH Serine protease inhibitors
EP3247376B1 (en) 2015-03-30 2021-07-14 Sunnybrook Research Institute Treating prostate cancer
US10573824B2 (en) * 2015-09-24 2020-02-25 Lg Chem, Ltd. Compound and organic electronic element comprising same
RU2727474C2 (ru) * 2015-10-06 2020-07-21 Редхилл Байофарма Лтд. Виды комбинированной терапии для лечения рака
KR20220151613A (ko) 2020-03-10 2022-11-15 레드힐 바이오파마 엘티디 코로나바이러스 감염의 치료
US11471448B2 (en) 2020-12-15 2022-10-18 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU541738B2 (en) * 1979-09-20 1985-01-17 Nippon Chemiphar Co. Ltd. Cyclohexane carboxylic acid derivatives
DE3577700D1 (de) * 1984-11-30 1990-06-21 Shosuke Okamoto Lysinderivat und proteinase-inhibitor.
CA2073776A1 (en) * 1990-11-15 1992-05-16 Joerg Stuerzebecher Meta-substituted phenyl alanine derivatives
DE59410179D1 (de) * 1993-02-10 2002-10-10 Pentapharm Ag Basel Piperazide von substituierten phenylalanin-derivativen als thrombin inhibitoren
US5550213A (en) * 1993-12-27 1996-08-27 Rutgers, The State University Of New Jersey Inhibitors of urokinase plasminogen activator
AU3107795A (en) * 1994-08-09 1996-03-07 Pentapharm Ag Inhibitors of the benzamidine type
DE9418185U1 (de) * 1994-11-12 1995-02-23 Richard Wolf Gmbh, 75438 Knittlingen Behälter für medizinische Instrumente
CH689611A5 (de) * 1995-03-01 1999-07-15 Pentapharm Ag Urokinase-Inhibitoren.
EP1114024B1 (de) 1998-09-18 2002-11-27 Pentapharm A.G. Urokinase-inhibitoren

Also Published As

Publication number Publication date
CA2338073A1 (en) 2000-02-03
AU5161599A (en) 2000-02-14
EP1098651A2 (de) 2001-05-16
DE59903981D1 (de) 2003-02-13
ATE230599T1 (de) 2003-01-15
PT1264828E (pt) 2004-08-31
AU754958B2 (en) 2002-11-28
ES2219607T3 (es) 2004-12-01
DE59909210D1 (de) 2004-05-19
EP1098651B1 (de) 2003-01-08
CA2338073C (en) 2010-09-21
EP1264828B1 (de) 2004-04-14
JP4603162B2 (ja) 2010-12-22
ES2189455T3 (es) 2003-07-01
WO2000004954A3 (de) 2000-06-22
US20030013723A1 (en) 2003-01-16
ATE264103T1 (de) 2004-04-15
WO2000004954A2 (de) 2000-02-03
BR9912327A (pt) 2001-05-02
JP2002521348A (ja) 2002-07-16
US6624169B1 (en) 2003-09-23
MXPA01000553A (es) 2002-04-24
US6680320B2 (en) 2004-01-20
EP1264828A1 (de) 2002-12-11

Similar Documents

Publication Publication Date Title
BR9912327B1 (pt) Inibidores da uroquinase
AU4437896A (en) Piperidine derivatives having tachykinin antagonist activity
Berkels et al. Amlodipine increases endothelial nitric oxide by dual mechanisms
AU2006313491B2 (en) Compositions and methods for treating thrombocytopenia
HUT75113A (en) 4-substituted piperidine derivatives useful as neurokinin antagonists
NO962543L (no) Cykliske amid-derivater som neurokinin A-antagonister
AR002971A1 (es) COMPUESTOS DE 3-(1,2,3,6)-TETRAHIDROPIRIDIN-4-ILO Y 3-PIPERIDIN-4-ILO-1H- INDOL, AGONISTAS DE 5HT(1f) FORMULACIONES FARMACEUTICAS QUE LOS CONTIENEN YMETODOS PARA ACTIVAR DICHOS RECEPTORES 5HT(1f) Y/O PARA TRATAR LAS MIGRANAS Y DESORDENES ASOCIADOS CON ELLA.
ES2095833T3 (es) Derivados de benzodiazepinas.
HUP0500173A2 (hu) Alfa-szulfonamido-acetamid-származékok mint béta-amiloid inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények
ATE364385T1 (de) Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
YU32196A (sh) Upotreba jedinjenja za pripremanje leka korisnog za inhibiranje migracije vaskularnih ćelija glatkog mišića
EA200000110A1 (ru) Бициклические бензамиды производных 3- или 4-замещенного 4-(аминометил) пиперидина с гастрокинетическими свойствами
ATE319705T1 (de) Chinolyl-propylpiperidinderivate und deren verwendung als antimikrobielle wirkstoffe
NO921831L (no) Indolderivater, fremgangsmaate for fremstilling derav samtpreparater inneholdende et slikt derivat
CA2439440A1 (en) Treatment of tuberous sclerosis associated neoplasms
HUP0100276A2 (hu) Szubsztituált krománszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ATE409187T1 (de) N-(substituierte benzyl)-8-hydroxy-1,6- naphthyridin-7- carbonsäureamide als hiv- integrase-hemmer
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
KR920701165A (ko) 골수세포형성 촉진에 유용한 헤테로아릴-3-옥소-프로판니트릴 유도체
DK0506434T3 (da) Thiazolidinon- og oxazolidinon-derivater, fremstilling deraf og deres anvendelse som vasodilaterende midler
IL106311A0 (en) 4-(3-benzofuranyl)piperidinyl and 4-(3-benzothienyl)piperidinyl derivatives,their preparation and pharmaceutical compositions containing them
NO982863L (no) Nye forbindelser med analgetisk effekt
CO5280088A1 (es) Inhibidores de proteasa
FR2757164B1 (fr) Nouveaux derives de n-benzylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE60120757D1 (de) 4-substituierte chinolone zur behandlung von autoimmunerkrankungen

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: WILEX AG (DE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020080117818/RJ DE 08/09/2008.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2236 DE 12.11.2013, QUANTO AO NOME E ENDERECO DO TITULAR

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/495 (2006.01), A61K 51/04 (2006.0

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2523 DE 14-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.